{"protocolSection":{"identificationModule":{"nctId":"NCT06212752","orgStudyIdInfo":{"id":"3475A-D77 Japan Extension"},"secondaryIdInfos":[{"id":"MK-3475A-D77","type":"OTHER","domain":"MSD"},{"id":"2022-501506-36-00","type":"OTHER","domain":"EU CT"},{"id":"jRCT2031230049","type":"OTHER","domain":"Japan Registry of Clinical Trials (jRCT)"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","officialTitle":"A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-06-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-11-06","type":"ACTUAL"},"completionDateStruct":{"date":"2028-05-22","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-01-09","studyFirstSubmitQcDate":"2024-01-09","studyFirstPostDateStruct":{"date":"2024-01-19","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-10-22","resultsFirstSubmitQcDate":"2025-10-22","resultsFirstPostDateStruct":{"date":"2025-11-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-10-22","lastUpdatePostDateStruct":{"date":"2025-11-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are pembrolizumab (+) berahyaluronidase alfa subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.","detailedDescription":"Japan extension study will require approximately six years which includes one additional year (beyond the global study's last participant last study related contact) from the time the first participant (or their legally acceptable representative) provides informed consent until the last participant's last study related contact to complete.\n\nThe Japan extension study will include participants previously enrolled in Japan in the global study for MK-3475A-D77 (NCT05722015) plus the study will continue to enroll participants in Japan until the sample size for participants in Japan reaches approximately 39.\n\nAs of Amendment 1 of the supplemental statistical analysis plan (effective date: 23 Aug 2024), patient reported outcomes will no longer be the secondary outcome measures of the study."},"conditionsModule":{"conditions":["Metastatic Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":39,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","type":"EXPERIMENTAL","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated with Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for18 cycles (up to approximately108 weeks) in combination with platinum doublet chemotherapy.","interventionNames":["Biological: Pembrolizumab (+) Berahyaluronidase alfa","Drug: Pemetrexed","Drug: Cisplatin","Drug: Carboplatin","Drug: Paclitaxel","Drug: Nab-paclitaxel","Drug: Filgrastim","Drug: Pegylated filgrastim"]},{"label":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","type":"ACTIVE_COMPARATOR","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Drug: Carboplatin","Drug: Paclitaxel","Drug: Nab-paclitaxel","Biological: Pembrolizumab","Drug: Filgrastim","Drug: Pegylated filgrastim"]}],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab (+) Berahyaluronidase alfa","description":"Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy"],"otherNames":["MK-3475A"]},{"type":"DRUG","name":"Pemetrexed","description":"Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"],"otherNames":["Alimta"]},{"type":"DRUG","name":"Cisplatin","description":"Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"],"otherNames":["Platinol-AQ"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"],"otherNames":["Taxol"]},{"type":"DRUG","name":"Nab-paclitaxel","description":"Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"],"otherNames":["Albumin-bound paclitaxel"]},{"type":"BIOLOGICAL","name":"Pembrolizumab","description":"Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.","armGroupLabels":["Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"],"otherNames":["MK-3475, KEYTRUDA"]},{"type":"DRUG","name":"Filgrastim","description":"Filgrastim will be administered as per the schedule specified for the arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"]},{"type":"DRUG","name":"Pegylated filgrastim","description":"Pegylated filgrastim will be administered as per the schedule specified for the arm.","armGroupLabels":["Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). The percentage of participants with CR or PR were reported.","timeFrame":"Up to ~ 16 months"}],"secondaryOutcomes":[{"measure":"Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose","description":"AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","timeFrame":"Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days4, 15, 29, and 42 postdose (cycle length = 42 days)"},{"measure":"Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State","description":"Ctrough is defined as the trough concentration at steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough.","timeFrame":"Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)"},{"measure":"Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose","description":"Cmax was defined as the maximum serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, geometric mean Cmax value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","timeFrame":"Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)"},{"measure":"Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose","description":"Ctrough was defined as the lowest serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Ctrough. Per protocol, geometric mean Ctrough value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","timeFrame":"At designated time points (Up to ~28 months)"},{"measure":"Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State","description":"AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.","timeFrame":"At designated time points (Up to ~28 months)"},{"measure":"Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State","description":"Cmax was defined as the maximum serum concentration of pembrolizumab reached at steady state. Blood samples were collected at pre-specified timepoints to determine Cmax. Per protocol, geometric mean Cmax value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.","timeFrame":"Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)"},{"measure":"Number of Participants Who Test Positive for Anti-Drug Antibodies (ADAs) for Pembrolizumab","description":"Blood samples are to be collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. The percentage of participants who develop anti pembrolizumab antibodies will be reported.","timeFrame":"At designated time points (Up to ~28 months)"},{"measure":"Progression-free Survival (PFS) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.","timeFrame":"Up to ~59 months"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization to death due to any cause.","timeFrame":"Up to ~59 months"},{"measure":"Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who show confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.","timeFrame":"Up to ~59 months"},{"measure":"Number of Participants Who Experienced at Least One Adverse Event (AE)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an AE will be reported for Arms 1 and 2.","timeFrame":"Up to~28 months"},{"measure":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported for Arms 1 and 2.","timeFrame":"Up to~25 months"}]},"eligibilityModule":{"eligibilityCriteria":"The key inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria:\n\n* Has histologically or cytologically confirmed diagnosis of squamous or non-squamous Non-small Cell Lung Cancer (NSCLC)\n* Must provide archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated\n* Has a life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* Has received prior systemic anticancer therapy for metastatic NSCLC\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization\n* Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicity requiring corticosteroids\n* Has received radiation therapy to the lung (\\>30 Gray) within 6 months of start of study intervention\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has an active infection requiring systemic therapy\n* Has a history of human immunodeficiency virus (HIV) infection\n* Has a history of Hepatitis B or C\n* Has not adequately recovered from major surgery or has ongoing surgical complications\n* Has a history of allogenic tissue/solid organ transplant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Fujita Health University ( Site 4406)","city":"Toyoake","state":"Aichi-ken","zip":"470-1192","country":"Japan","geoPoint":{"lat":35.038,"lon":136.99931}},{"facility":"Kurume University Hospital ( Site 4412)","city":"Kurume","state":"Fukuoka","zip":"830-0011","country":"Japan","geoPoint":{"lat":33.31667,"lon":130.51667}},{"facility":"Gunma Prefectural Cancer Center ( Site 4416)","city":"Otashi","state":"Gunma","zip":"373-8550","country":"Japan"},{"facility":"National Hospital Organization Hokkaido Cancer Center ( Site 4415)","city":"Sapporo","state":"Hokkaido","zip":"003-0804","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Kanagawa Cardiovascular and Respiratory Center ( Site 4404)","city":"Yokohama","state":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Miyagi Cancer Center ( Site 4401)","city":"Natori-shi","state":"Miyagi","zip":"981-1293","country":"Japan","geoPoint":{"lat":38.16667,"lon":140.88333}},{"facility":"Sendai Kousei Hospital ( Site 4400)","city":"Sendai","state":"Miyagi","zip":"9800873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Kurashiki Central Hospital ( Site 4409)","city":"Kurashiki","state":"Okayama-ken","zip":"710-8602","country":"Japan","geoPoint":{"lat":34.58333,"lon":133.76667}},{"facility":"Kansai Medical University Hospital ( Site 4408)","city":"Hirakata","state":"Osaka","zip":"573-1191","country":"Japan","geoPoint":{"lat":34.81352,"lon":135.64914}},{"facility":"Osaka Medical and Pharmaceutical University Hospital ( Site 4414)","city":"Takatsuki","state":"Osaka","zip":"569-8686","country":"Japan","geoPoint":{"lat":34.84833,"lon":135.61678}},{"facility":"Saitama Prefectural Cancer Center ( Site 4402)","city":"Ina-machi","state":"Saitama","zip":"362-0806","country":"Japan"},{"facility":"Shizuoka Cancer Center ( Site 4405)","city":"Nagaizumi-cho,Sunto-gun","state":"Shizuoka","zip":"411-8777","country":"Japan"},{"facility":"Tochigi Cancer Center ( Site 4417)","city":"Utsunomiya","state":"Tochigi","zip":"320-0834","country":"Japan","geoPoint":{"lat":36.56667,"lon":139.88333}},{"facility":"Juntendo University Hospital ( Site 4413)","city":"Bunkyo-ku","state":"Tokyo","zip":"1138431","country":"Japan"},{"facility":"National Hospital Organization Kyushu Medical Center ( Site 4411)","city":"Fukuoka","zip":"810-8563","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"National Hospital Organization Kyushu Cancer Center ( Site 4410)","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Osaka International Cancer Institute ( Site 4407)","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Nippon Medical School Hospital ( Site 4403)","city":"Tokyo","zip":"113-8603","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf","url":"https://externaldatasharing-msd.com/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"39 Japanese participants were randomized and received treatment (global study \\[NCT05722015; n=23\\] or to the extension portion \\[n=16\\]).","groups":[{"id":"FG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"FG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"11"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Participants ongoing","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"8"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion.","groups":[{"id":"BG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"BG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"39"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.3","spread":"9.0"},{"groupId":"BG001","value":"70.7","spread":"8.2"},{"groupId":"BG002","value":"69.0","spread":"8.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"32"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"39"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"39"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Randomization of participants in the study was stratified by an ECOG Performance Status of 0 (Fully active, able to carry on all pre-disease performance without restriction) or 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"ECOG = 0","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"24"}]},{"title":"ECOG = 1","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"Histology (squamous vs. nonsquamous)","description":"Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Non-squamous","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"23"}]},{"title":"Squamous","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"16"}]}]}]},{"title":"Programmed Cell Death Ligand 1 (PD-L1) Status","description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Randomization of participants in the study was stratified by PD-L1 tumor proportion score (TPS) at baseline (\\<1%, 1-49%, ≥50% or Unknown). Higher percentages of PD-L1 TPS staining correspond to higher positivity of PD-L1 on a tumor.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"TPS <1%","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"18"}]},{"title":"TPS 1-49%","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"15"}]},{"title":"TPS ≥50%","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). The percentage of participants with CR or PR were reported.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Up to ~ 16 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","lowerLimit":"44.1","upperLimit":"81.4"},{"groupId":"OG001","value":"18.2","lowerLimit":"2.3","upperLimit":"51.8"}]}]}]},{"type":"SECONDARY","title":"Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose","description":"AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion who received a dose in Cycle 1 with at least 1 valid postdose pharmacokinetic (PK) sample available in Cycle1 and for whom a model-based assessment of AUC0-6 weeks could be made.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg·day/mL","timeFrame":"Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days4, 15, 29, and 42 postdose (cycle length = 42 days)","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1864.76","spread":"22.18"},{"groupId":"OG001","value":"1697.98","spread":"18.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin is 0.8.","paramType":"Geometric Mean Ratio (GMR)","paramValue":"1.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.95","ciUpperLimit":"1.27","estimateComment":"GMR and associated 96% confidence interval (Cl) were calculated using the Welch's t test. GMR was calculated as geometric mean (GM) of Pembrolizumab Formulated with Berahyaluronidase Alfa to GM of Pembrolizumab."}]},{"type":"SECONDARY","title":"Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State","description":"Ctrough is defined as the trough concentration at steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion who received a dose in Cycle 1 and Cycle 3 with at least 1 valid postdose PK sample available in Cycle 1through Cycle 3 and for whom a model-based assessment of Ctrough could be made.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/ml","timeFrame":"Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.11","spread":"35.58"},{"groupId":"OG001","value":"30.86","spread":"24.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin is 0.8.","paramType":"GMR","paramValue":"1.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.14","ciUpperLimit":"1.88","estimateComment":"GMR and associated 95% CI were calculated using the Welch's t test. GMR was calculated as geometric mean (GM) of Pembrolizumab Formulated with Berahyaluronidase Alfa to GM of Pembrolizumab."}]},{"type":"SECONDARY","title":"Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose","description":"Cmax was defined as the maximum serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, geometric mean Cmax value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion who received who received a dose in Cycle 1 with at least 1 valid postdose PK sample available in Cycle 1 and for whom a model-based assessment of Cmax could be made.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/ml","timeFrame":"Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.54","spread":"23.7"},{"groupId":"OG001","value":"141.9","spread":"16.4"}]}]}]},{"type":"SECONDARY","title":"Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose","description":"Ctrough was defined as the lowest serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Ctrough. Per protocol, geometric mean Ctrough value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion who received a dose in Cycle 1 with at least 1 valid postdose PK sample available in Cycle 1 and for whom a model-based assessment of Ctrough could be made.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/ml","timeFrame":"At designated time points (Up to ~28 months)","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.62","spread":"27.9"},{"groupId":"OG001","value":"16.27","spread":"29.7"}]}]}]},{"type":"SECONDARY","title":"Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State","description":"AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion who received a dose in Cycle 1 and Cycle 3 with at least 1 valid postdose PK sample available in Cycle 1 through Cycle 3 and for whom a model-based assessment of AUC0-6 weeks could be made.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg•day/ml","timeFrame":"At designated time points (Up to ~28 months)","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3116","spread":"27.3"},{"groupId":"OG001","value":"2514","spread":"17.3"}]}]}]},{"type":"SECONDARY","title":"Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State","description":"Cmax was defined as the maximum serum concentration of pembrolizumab reached at steady state. Blood samples were collected at pre-specified timepoints to determine Cmax. Per protocol, geometric mean Cmax value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.","populationDescription":"All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion who received a dose in Cycle 1 and Cycle 3 with at least 1 valid postdose PK sample available in Cycle 1 through Cycle 3 and for whom a model-based assessment of Cmax could be made.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/mL","timeFrame":"Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."},{"id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.1","spread":"25.3"},{"groupId":"OG001","value":"159.8","spread":"13.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Test Positive for Anti-Drug Antibodies (ADAs) for Pembrolizumab","description":"Blood samples are to be collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. The percentage of participants who develop anti pembrolizumab antibodies will be reported.","reportingStatus":"NOT_POSTED","timeFrame":"At designated time points (Up to ~28 months)","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Progression-free Survival (PFS) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.","reportingStatus":"NOT_POSTED","timeFrame":"Up to ~59 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization to death due to any cause.","reportingStatus":"NOT_POSTED","timeFrame":"Up to ~59 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who show confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.","reportingStatus":"NOT_POSTED","timeFrame":"Up to ~59 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants Who Experienced at Least One Adverse Event (AE)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an AE will be reported for Arms 1 and 2.","reportingStatus":"NOT_POSTED","timeFrame":"Up to~28 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported for Arms 1 and 2.","reportingStatus":"NOT_POSTED","timeFrame":"Up to~25 months","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to approximately 16 months","description":"All-Cause Mortality includes all randomized Japanese participants. Serious \\& Other adverse events (AEs) include all randomized Japanese participants who received ≥1 dose of study drug. Per protocol, disease progression of cancer was not considered an AE unless considered related to study treatment. MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" \\& \"Disease progression\" not related to study treatment were excluded as AEs. Data were reported by treatment received.","eventGroups":[{"id":"EG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.","deathsNumAffected":5,"deathsNumAtRisk":28,"seriousNumAffected":12,"seriousNumAtRisk":28,"otherNumAffected":28,"otherNumAtRisk":28},{"id":"EG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","description":"Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.","deathsNumAffected":3,"deathsNumAtRisk":11,"seriousNumAffected":3,"seriousNumAtRisk":11,"otherNumAffected":11,"otherNumAtRisk":11}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pneumomediastinum","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":28},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":11}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":6,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":11}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":13,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":11}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":9,"numAtRisk":28},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":11}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Epiretinal membrane","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Punctate keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":11}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":11}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":11}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":10,"numAtRisk":28},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":11}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":11}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":11}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":11}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":11}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":28},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":11}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":11}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":11}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":11}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":11}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":11}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":11}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":11}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Hyperphosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":11}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":11}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":11}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":11}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":11}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":11}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":11}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Xeroderma","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":11}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":11}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The results of this study may be published or presented at scientific meetings. The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Any information identified by the Sponsor as confidential must be deleted prior to submission."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-02-06","uploadDate":"2025-10-22T11:28","filename":"Prot_000.pdf","size":1885346},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-08-23","uploadDate":"2025-10-22T11:28","filename":"SAP_001.pdf","size":523276}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D000068196","term":"Albumin-Bound Paclitaxel"},{"id":"D000069585","term":"Filgrastim"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D000418","term":"Albumins"},{"id":"D011506","term":"Proteins"},{"id":"D016179","term":"Granulocyte Colony-Stimulating Factor"},{"id":"D003115","term":"Colony-Stimulating Factors"},{"id":"D006023","term":"Glycoproteins"},{"id":"D006001","term":"Glycoconjugates"},{"id":"D002241","term":"Carbohydrates"},{"id":"D016298","term":"Hematopoietic Cell Growth Factors"},{"id":"D016207","term":"Cytokines"},{"id":"D036341","term":"Intercellular Signaling Peptides and Proteins"},{"id":"D010455","term":"Peptides"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}